133 related articles for article (PubMed ID: 9511180)
1. A rare CYP19 (aromatase) variant may increase the risk of breast cancer.
Kristensen VN; Andersen TI; Lindblom A; Erikstein B; Magnus P; Børresen-Dale AL
Pharmacogenetics; 1998 Feb; 8(1):43-8. PubMed ID: 9511180
[TBL] [Abstract][Full Text] [Related]
2. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.
Haiman CA; Hankinson SE; Spiegelman D; De Vivo I; Colditz GA; Willett WC; Speizer FE; Hunter DJ
Int J Cancer; 2000 Jul; 87(2):204-10. PubMed ID: 10861475
[TBL] [Abstract][Full Text] [Related]
3. CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women.
Ribeiro FS; de Amorim LM; de Almeida Simão T; Mendonça GA; de Moura Gallo CV; Pinto LF
Toxicol Lett; 2006 Jun; 164(1):90-5. PubMed ID: 16406421
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic variation in CYP19 and the risk of breast cancer.
Baxter SW; Choong DY; Eccles DM; Campbell IG
Carcinogenesis; 2001 Feb; 22(2):347-9. PubMed ID: 11181459
[TBL] [Abstract][Full Text] [Related]
5. Aromatase and breast cancer susceptibility.
Probst-Hensch NM; Ingles SA; Diep AT; Haile RW; Stanczyk FZ; Kolonel LN; Henderson BE
Endocr Relat Cancer; 1999 Jun; 6(2):165-73. PubMed ID: 10731105
[TBL] [Abstract][Full Text] [Related]
6. Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population.
Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Ohtake N; Takei T; Nakata S; Hasumi M; Yamanaka H
Anticancer Res; 2003; 23(6D):4941-6. PubMed ID: 14981949
[TBL] [Abstract][Full Text] [Related]
7. The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women.
Kim JY; Lee CS; Kim HO; Jo YH; Lee J; Jung MH; Baik HH; Choe W; Kang I; Yoon KS
Oncol Rep; 2009 Sep; 22(3):487-92. PubMed ID: 19639193
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk.
Healey CS; Dunning AM; Durocher F; Teare D; Pharoah PD; Luben RN; Easton DF; Ponder BA
Carcinogenesis; 2000 Feb; 21(2):189-93. PubMed ID: 10657957
[TBL] [Abstract][Full Text] [Related]
9. The association of aromatase (CYP19) gene variants with sperm concentration and motility.
Lazaros L; Xita N; Kaponis A; Hatzi E; Plachouras N; Sofikitis N; Zikopoulos K; Georgiou I
Asian J Androl; 2011 Mar; 13(2):292-7. PubMed ID: 21217768
[TBL] [Abstract][Full Text] [Related]
10. CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
Tüzüner BM; Oztürk T; Kisakesen HI; Ilvan S; Zerrin C; Oztürk O; Isbir T
In Vivo; 2010; 24(1):71-4. PubMed ID: 20133979
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risk associated with polymorphism in CYP19 in Japanese women.
Miyoshi Y; Iwao K; Ikeda N; Egawa C; Noguchi S
Int J Cancer; 2000 Jul; 89(4):325-8. PubMed ID: 10956405
[TBL] [Abstract][Full Text] [Related]
12. A tetranucleotide repeat polymorphism in the CYP19 gene and breast cancer susceptibility in a Greek population exposed and not exposed to pesticides.
Dialyna I; Tzanakakis G; Dolapsakis G; Tsatsakis A
Toxicol Lett; 2004 Jun; 151(1):267-71. PubMed ID: 15177662
[TBL] [Abstract][Full Text] [Related]
13. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk.
Miyoshi Y; Ando A; Hasegawa S; Ishitobi M; Yamamura J; Irahara N; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Eur J Cancer; 2003 Nov; 39(17):2531-7. PubMed ID: 14602139
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants of CYP19 (aromatase) and breast cancer risk.
Kristensen VN; Harada N; Yoshimura N; Haraldsen E; Lonning PE; Erikstein B; Kåresen R; Kristensen T; Børresen-Dale AL
Oncogene; 2000 Mar; 19(10):1329-33. PubMed ID: 10713674
[TBL] [Abstract][Full Text] [Related]
15. Distinct prevalence of the CYP19 Delta3(TTTA)(7) allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals.
Suspitsin EN; Grigoriev MY; Togo AV; Kuligina ES; Belogubova EV; Pozharisski KM; Chagunava OL; Sokolov EP; Theillet C; Berstein LM; Hanson KP; Imyanitov EN
Eur J Cancer; 2002 Sep; 38(14):1911-6. PubMed ID: 12204674
[TBL] [Abstract][Full Text] [Related]
16. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients.
Agarwal VR; Bulun SE; Leitch M; Rohrich R; Simpson ER
J Clin Endocrinol Metab; 1996 Nov; 81(11):3843-9. PubMed ID: 8923826
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.
Han DF; Zhou X; Hu MB; Xie W; Mao ZF; Chen DE; Liu F; Zheng F
Chin Med J (Engl); 2005 Sep; 118(18):1507-16. PubMed ID: 16232327
[TBL] [Abstract][Full Text] [Related]
18. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.
Huang CS; Kuo SH; Lien HC; Yang SY; You SL; Shen CY; Lin CH; Lu YS; Chang KJ
Oncologist; 2008 Jul; 13(7):751-60. PubMed ID: 18614591
[TBL] [Abstract][Full Text] [Related]
19. The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese.
Hirose K; Matsuo K; Toyama T; Iwata H; Hamajima N; Tajima K
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1407-11. PubMed ID: 15298966
[TBL] [Abstract][Full Text] [Related]
20. CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study.
Thyagarajan B; Brott M; Mink P; Folsom AR; Anderson KE; Oetting WS; Gross M
Cancer Lett; 2004 Apr; 207(2):183-9. PubMed ID: 15072827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
